• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Kewaunee Scientific Corporation

    3/31/25 4:23:01 PM ET
    $KEQU
    Medical Specialities
    Industrials
    Get the next $KEQU alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001775052
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    KEWAUNEE SCIENTIFIC CORP /DE/
    SEC File Number
    000-05286
    Address of Issuer
    2700 W FRONT ST
    STATESVILLE
    NORTH CAROLINA
    28677
    Phone
    7048737202
    Name of Person for Whose Account the Securities are To Be Sold
    Gardner Donald T. III
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    1000
    Fidelity Brokerage Services LLC
    245 Summer Street
    Boston � MA � 02110
    100038940.00285446303/31/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/21/2022Stock AwardIssuerCheckbox not checked94406/21/2022Compensation
    06/21/202206/29/2022Stock AwardIssuerCheckbox not checked5606/29/2022Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Gardner Donald T. III
    2700 W FRONT ST
    STATESVILLE � NC � 28677
    Common01/10/2025125774448.00
    Gardner Donald T. III
    2700 W FRONT ST,
    STATESVILLE � NC � 28677
    Common03/26/20253000119981.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/31/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Cristina Garcia, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Gardner Donald T. III

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $KEQU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KEQU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KEQU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kewaunee Scientific Corporation

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      11/1/24 9:14:13 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 11:44:29 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 9:59:14 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pyle Margaret B was granted 1,896 shares (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 1:33:49 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Russell John was granted 1,896 shares, increasing direct ownership by 6% to 34,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:58:43 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M was granted 1,896 shares, increasing direct ownership by 10% to 20,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:56:19 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    SEC Filings

    See more
    • SEC Form SD filed by Kewaunee Scientific Corporation

      SD - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      5/9/25 10:54:08 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 144 filed by Kewaunee Scientific Corporation

      144 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      3/31/25 4:23:01 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 10-Q filed by Kewaunee Scientific Corporation

      10-Q - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      3/14/25 10:22:53 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kewaunee Scientific Announces Amendment to Share Repurchase Program

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced an amendment to its existing share repurchase program. On March 12, 2025, the Board of Directors of Kewaunee Scientific Corporation (the "Company") amended its existing share repurchase program initially approved on August 31, 2023, and in effect September 1, 2023. The Board of Directors authorized the repurchase of up to an additional 100,000 shares of the Company's common stock under the existing share repurchase program, as amended (the "Program"), which does not

      3/12/25 5:08:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2025

      STATESVILLE, N.C., Feb. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company plans to release its third quarter fiscal year 2025 financial results on Wednesday, March 12, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's produc

      2/26/25 5:21:00 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gehl Keith M bought $35,000 worth of shares (1,000 units at $35.00), increasing direct ownership by 6% to 18,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      4/7/25 10:57:11 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $22,500 worth of shares (500 units at $45.00), increasing direct ownership by 3% to 17,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/24/25 4:32:54 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $19,747 worth of shares (403 units at $49.00), increasing direct ownership by 2% to 17,000 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/18/25 3:20:26 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Financials

    Live finance-specific insights

    See more
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

      STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024. Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter.

      12/11/24 4:04:00 PM ET
      $KEQU
      Medical Specialities
      Industrials